Cargando…

Population-Based Registry Analysis of Antidiabetics Dispensations: Trend Use in Spain between 2015 and 2018 with Reference to Driving

Insulins and some oral antidiabetics are considered to be driving-impairing medicines (DIM) and they belong to the Driving under the Influence of Drugs, alcohol, and medicines (DRUID) category I (minor influence on fitness to drive). The trend of antidiabetics use in Castilla y León from 2015 to 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Gutiérrez-Abejón, Eduardo, Criado-Espegel, Paloma, Herrera-Gómez, Francisco, Álvarez, F. Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464462/
https://www.ncbi.nlm.nih.gov/pubmed/32722515
http://dx.doi.org/10.3390/ph13080165
_version_ 1783577370949582848
author Gutiérrez-Abejón, Eduardo
Criado-Espegel, Paloma
Herrera-Gómez, Francisco
Álvarez, F. Javier
author_facet Gutiérrez-Abejón, Eduardo
Criado-Espegel, Paloma
Herrera-Gómez, Francisco
Álvarez, F. Javier
author_sort Gutiérrez-Abejón, Eduardo
collection PubMed
description Insulins and some oral antidiabetics are considered to be driving-impairing medicines (DIM) and they belong to the Driving under the Influence of Drugs, alcohol, and medicines (DRUID) category I (minor influence on fitness to drive). The trend of antidiabetics use in Castilla y León from 2015 to 2018 is presented through a population-based registry study. Treatment duration with these medicines and the concomitant use of other DIMs were observed. An adjustment method was used with information from the drivers’ license census. For all calculations, age and gender were taken into account. 3.98% of the general population used at least one antidiabetic, as well as 2.92% of drivers. The consumption of antidiabetics in men was higher than in women (4.35% vs. 3.61%, p = 0.001), and the use increases with age, especially from 35–39 years to 75–79 years in men and 85–89 years in women. Antidiabetics were consumed chronically, specifically 100% in the case of insulins and 95% in the case of oral antidiabetics. In addition to antidiabetics, 2.5 ± 1.86 DIMs were consumed, mainly anxiolytics (25.53%), opioids (23.03%), other analgesics and antipiretics (19.13%), and antidepressants (17.73%). Collaboration between pharmacists and physicians is a priority to clearly transmitting risks to patients. It is necessary that the health authorities include information on DIMs, such as the DRUID classification, in the prescription and dispensing software.
format Online
Article
Text
id pubmed-7464462
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74644622020-09-04 Population-Based Registry Analysis of Antidiabetics Dispensations: Trend Use in Spain between 2015 and 2018 with Reference to Driving Gutiérrez-Abejón, Eduardo Criado-Espegel, Paloma Herrera-Gómez, Francisco Álvarez, F. Javier Pharmaceuticals (Basel) Article Insulins and some oral antidiabetics are considered to be driving-impairing medicines (DIM) and they belong to the Driving under the Influence of Drugs, alcohol, and medicines (DRUID) category I (minor influence on fitness to drive). The trend of antidiabetics use in Castilla y León from 2015 to 2018 is presented through a population-based registry study. Treatment duration with these medicines and the concomitant use of other DIMs were observed. An adjustment method was used with information from the drivers’ license census. For all calculations, age and gender were taken into account. 3.98% of the general population used at least one antidiabetic, as well as 2.92% of drivers. The consumption of antidiabetics in men was higher than in women (4.35% vs. 3.61%, p = 0.001), and the use increases with age, especially from 35–39 years to 75–79 years in men and 85–89 years in women. Antidiabetics were consumed chronically, specifically 100% in the case of insulins and 95% in the case of oral antidiabetics. In addition to antidiabetics, 2.5 ± 1.86 DIMs were consumed, mainly anxiolytics (25.53%), opioids (23.03%), other analgesics and antipiretics (19.13%), and antidepressants (17.73%). Collaboration between pharmacists and physicians is a priority to clearly transmitting risks to patients. It is necessary that the health authorities include information on DIMs, such as the DRUID classification, in the prescription and dispensing software. MDPI 2020-07-25 /pmc/articles/PMC7464462/ /pubmed/32722515 http://dx.doi.org/10.3390/ph13080165 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gutiérrez-Abejón, Eduardo
Criado-Espegel, Paloma
Herrera-Gómez, Francisco
Álvarez, F. Javier
Population-Based Registry Analysis of Antidiabetics Dispensations: Trend Use in Spain between 2015 and 2018 with Reference to Driving
title Population-Based Registry Analysis of Antidiabetics Dispensations: Trend Use in Spain between 2015 and 2018 with Reference to Driving
title_full Population-Based Registry Analysis of Antidiabetics Dispensations: Trend Use in Spain between 2015 and 2018 with Reference to Driving
title_fullStr Population-Based Registry Analysis of Antidiabetics Dispensations: Trend Use in Spain between 2015 and 2018 with Reference to Driving
title_full_unstemmed Population-Based Registry Analysis of Antidiabetics Dispensations: Trend Use in Spain between 2015 and 2018 with Reference to Driving
title_short Population-Based Registry Analysis of Antidiabetics Dispensations: Trend Use in Spain between 2015 and 2018 with Reference to Driving
title_sort population-based registry analysis of antidiabetics dispensations: trend use in spain between 2015 and 2018 with reference to driving
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464462/
https://www.ncbi.nlm.nih.gov/pubmed/32722515
http://dx.doi.org/10.3390/ph13080165
work_keys_str_mv AT gutierrezabejoneduardo populationbasedregistryanalysisofantidiabeticsdispensationstrenduseinspainbetween2015and2018withreferencetodriving
AT criadoespegelpaloma populationbasedregistryanalysisofantidiabeticsdispensationstrenduseinspainbetween2015and2018withreferencetodriving
AT herreragomezfrancisco populationbasedregistryanalysisofantidiabeticsdispensationstrenduseinspainbetween2015and2018withreferencetodriving
AT alvarezfjavier populationbasedregistryanalysisofantidiabeticsdispensationstrenduseinspainbetween2015and2018withreferencetodriving